Pharmaceutical Companies
-
Genmab halts phase 1/2 trial for oncology candidate GEN1160 amid broader strategic review
GEN1160 now joins GEN1107 on Genmab’s list of discontinued assets from the April 2024 ProfoundBio acquisition.
-
Moderna axes three clinical-stage mRNA candidates to focus R&D on oncology
A company spokesperson explained that Moderna has “prioritized our pipeline and R&D investments as part of our broader cost efficiency efforts,” though the company provided no additional details about the specific discontinuations.
-
Merck KGaA enters USD3B AI drug discovery partnership with Valo Health to target Parkinson’s disease
Through this partnership, Merck gains access to Valo’s advanced AI-powered human causal biology and discovery platforms, which the drugmaker will use to identify new disease targets and develop preclinical compounds.
-
Syntegon reports 19% sales growth in Q3 2025 driven by pharma innovation
The company’s Pharma business unit led the strong performance, delivering sales growth of 32%, including 20% organic growth.
-
AstraZeneca commits USD2B to expand Maryland manufacturing operations
The new facility will produce molecules for medical trials. These expansions will create 200 additional jobs in Frederick and 100 more in Gaithersburg.